Готові списки джерел за темами / Combination drug therapies

Добірка наукової літератури з теми "Combination drug therapies"

Автор: Grafiati
Опубліковано: 10 грудня 2022
Оновлено: 29 січня 2023

Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями

Оберіть тип джерела:

Зміст

Ознайомтеся зі списками актуальних статей, книг, дисертацій, тез та інших наукових джерел на тему "Combination drug therapies".

Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.

Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.

Статті в журналах з теми "Combination drug therapies"

1

Hoeller, Christoph. "The future of combination therapies in advanced melanoma." memo - Magazine of European Medical Oncology 13, no. 3 (August 14, 2020): 309–13. http://dx.doi.org/10.1007/s12254-020-00640-x.

Повний текст джерела
Анотація:
Summary The combination of Cytotoxic T-Lymphozyte Antigen-4 (CTLA‑4) and Programmed death-1 (PD‑1) antibodies and the combination of BRAF and MEK inhibitors are the current clinical standards for combination immune and targeted therapy for melanoma, respectively. The success of these therapies has stimulated research into novel drug combinations for melanoma, of which a large majority are based on combination with PD‑1 or PD-Ligand 1 (PD-L1) blocking drugs. Thus, the aim is to provide an overview of the most important combination strategies in late stage clinical development and an outlook on drug combinations in early development that might enter larger clinical trials within the next few years.
Стилі APA, Harvard, Vancouver, ISO та ін.
2

Rideout, Todd C., Scott V. Harding, Christopher P. F. Marinangeli, and Peter J. H. Jones. "Combination drug–diet therapies for dyslipidemia." Translational Research 155, no. 5 (May 2010): 220–27. http://dx.doi.org/10.1016/j.trsl.2009.12.005.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
3

Plana, Deborah, Adam C. Palmer, and Peter K. Sorger. "Independent Drug Action in Combination Therapy: Implications for Precision Oncology." Cancer Discovery 12, no. 3 (March 1, 2022): 606–24. http://dx.doi.org/10.1158/2159-8290.cd-21-0212.

Повний текст джерела
Анотація:
Abstract Combination therapies are superior to monotherapy for many cancers. This advantage was historically ascribed to the ability of combinations to address tumor heterogeneity, but synergistic interaction is now a common explanation as well as a design criterion for new combinations. We review evidence that independent drug action, described in 1961, explains the efficacy of many practice-changing combination therapies: it provides populations of patients with heterogeneous drug sensitivities multiple chances of benefit from at least one drug. Understanding response heterogeneity could reveal predictive or pharmacodynamic biomarkers for more precise use of existing drugs and realize the benefits of additivity or synergy. Significance: The model of independent drug action represents an effective means to predict the magnitude of benefit likely to be observed in new clinical trials for combination therapies. The “bet-hedging” strategy implicit in independent action suggests that individual patients often benefit from only a subset—sometimes one—of the drugs in a combination. Personalized, targeted combination therapy, consisting of agents likely to be active in a particular patient, will increase, perhaps substantially, the magnitude of therapeutic benefit. Precision approaches of this type will require a better understanding of variability in drug response and new biomarkers, which will entail preclinical research on diverse panels of cancer models rather than studying drug synergy in unusually sensitive models.
Стилі APA, Harvard, Vancouver, ISO та ін.
4

Webster, Rachel M. "Combination therapies in oncology." Nature Reviews Drug Discovery 15, no. 2 (February 2016): 81–82. http://dx.doi.org/10.1038/nrd.2016.3.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
5

Blumer, Vanessa, and Muthiah Vaduganathan. "A rationale for dedicated trials of combination therapy in heart failure." European Heart Journal Supplements 24, Supplement_L (December 1, 2022): L49—L52. http://dx.doi.org/10.1093/eurheartjsupp/suac116.

Повний текст джерела
Анотація:
Abstract As heart failure (HF) enters a new era with high level of evidence supporting the use of individual drug therapies, we put forth a rationale for the need for dedicated investigation of the safety, tolerability, and practicalities associated with combination medical therapy. Being able to tailor therapies via combination approaches might offer a way to maximize benefits of available therapies and also facilitate compliance. The evidentiary bar to support multi-drug regimens should be raised in HF for a variety of reasons: (1) Pivotal HF randomized controlled trials (RCTs) to date have not traditionally tested and proven safety and efficacy of drug combinations, (2) HF patients have variable disease trajectories, (3) There is hesitancy by clinicians and patients to using multiple drugs and such trials may build confidence in their use, and (4) HF therapies have overlapping side effects. Similar to combination therapies being developed and tested in adjacent fields of medicine, HF care too would greatly benefit from dedicated investigations of combination treatment approaches. Personalizing precision medicine with combination therapies has the potential to further improve outcomes and facilitate optimal implementation of disease-modifying therapies in HF.
Стилі APA, Harvard, Vancouver, ISO та ін.
6

Gilad, Yosi, Gary Gellerman, David M. Lonard, and Bert W. O’Malley. "Drug Combination in Cancer Treatment—From Cocktails to Conjugated Combinations." Cancers 13, no. 4 (February 7, 2021): 669. http://dx.doi.org/10.3390/cancers13040669.

Повний текст джерела
Анотація:
It is well recognized today that anticancer drugs often are most effective when used in combination. However, the establishment of chemotherapy as key modality in clinical oncology began with sporadic discoveries of chemicals that showed antiproliferative properties and which as a first attempt were used as single agents. In this review we describe the development of chemotherapy from its origins as a single drug treatment with cytotoxic agents to polydrug therapy that includes targeted drugs. We discuss the limitations of the first chemotherapeutic drugs as a motivation for the establishment of combined drug treatment as standard practice in spite of concerns about frequent severe, dose limiting toxicities. Next, we introduce the development of targeted treatment as a concept for advancement within the broader field of small-molecule drug combination therapy in cancer and its accelerating progress that was boosted by recent scientific and technological progresses. Finally, we describe an alternative strategy of drug combinations using drug-conjugates for selective delivery of cytotoxic drugs to tumor cells that potentiates future improvement of drug combinations in cancer treatment. Overall, in this review we outline the development of chemotherapy from a pharmacological perspective, from its early stages to modern concepts of using targeted therapies for combinational treatment.
Стилі APA, Harvard, Vancouver, ISO та ін.
7

Yordanova, Anna, and Hojjat Ahmadzadehfar. "Combination Therapies with PRRT." Pharmaceuticals 14, no. 10 (September 30, 2021): 1005. http://dx.doi.org/10.3390/ph14101005.

Повний текст джерела
Анотація:
Peptide receptor radionuclide therapy (PRRT) is a successful targeted radionuclide therapy in neuroendocrine tumors (NETs). However, complete responses remain elusive. Combined treatments anticipate synergistic effects and thus better responses by combining ionizing radiation with other anti-tumor treatments. Furthermore, multimodal therapies often have a balanced toxicity profile. To date, few studies have evaluated the effect of combination therapies with PRRT, some of them phase I/II trials. This review will focus on several clinically tested, tailored approaches to improving the effects of PRRT. The aim is to help clinicians in the treatment planning of NETs to choose the most effective and safe treatment for each patient in the sense of personalized medicine. Current promising combination partners of PRRT are somatostatin analogues (SSAs), chemotherapy, molecular targeted treatment, liver radioembolization, and dual radionuclide PRRT (Lutetium-177-PRRT combined with Yttrium-90-PRRT).
Стилі APA, Harvard, Vancouver, ISO та ін.
8

Azam, Faruque, and Alexei Vazquez. "Trends in Phase II Trials for Cancer Therapies." Cancers 13, no. 2 (January 7, 2021): 178. http://dx.doi.org/10.3390/cancers13020178.

Повний текст джерела
Анотація:
Background: Drug combinations are the standard of care in cancer treatment. Identifying effective cancer drug combinations has become more challenging because of the increasing number of drugs. However, a substantial number of cancer drugs stumble at Phase III clinical trials despite exhibiting favourable efficacy in the earlier Phase. Methods: We analysed recent Phase II cancer trials comprising 2165 response rates to uncover trends in cancer therapies and used a null model of non-interacting agents to infer synergistic and antagonistic drug combinations. We compared our latest efficacy dataset with a previous dataset to assess the progress of cancer therapy. Results: Targeted therapies reach higher response rates when used in combination with cytotoxic drugs. We identify four synergistic and 10 antagonistic combinations based on the observed and expected response rates. We demonstrate that recent targeted agents have not significantly increased the response rates. Conclusions: We conclude that either we are not making progress or response rate measured by tumour shrinkage is not a reliable surrogate endpoint for the targeted agents.
Стилі APA, Harvard, Vancouver, ISO та ін.
9

Pettus, Kevin, Samera Sharpe, and John R. Papp. "In VitroAssessment of Dual Drug Combinations To Inhibit Growth of Neisseria gonorrhoeae." Antimicrobial Agents and Chemotherapy 59, no. 4 (January 26, 2015): 2443–45. http://dx.doi.org/10.1128/aac.04127-14.

Повний текст джерела
Анотація:
ABSTRACTThe development of resistance to first-line antimicrobial therapies has led to recommendations for combination therapies for the treatment of gonorrhea infection. Recent studies have shown the success of combination therapies in treating patients, but few have reported on thein vitroactivities of these drug combinations. Anin vitroassessment of azithromycin in combination with gentamicin demonstrated inhibition of growth and suggests that clinical trials may be warranted to assess the utility of this combination in treating gonorrhea infections.
Стилі APA, Harvard, Vancouver, ISO та ін.
10

Hwangbo, Haeun, and Adam C. Palmer. "Abstract 2739: Defining and evaluating drug additivity in clinical trials of combination cancer therapy." Cancer Research 82, no. 12_Supplement (June 15, 2022): 2739. http://dx.doi.org/10.1158/1538-7445.am2022-2739.

Повний текст джерела
Анотація:
Abstract BACKGROUND The benefits of combination therapy are often attributed to synergy, that is, drug interactions resulting in an anti-cancer effect that is more than the sum of its parts. Accordingly, the rationale for designing new drug combinations is often based on synergy measured in preclinical models. However, preclinical metrics of drug interaction are not applicable to clinical trial data, and there has been no established quantitative method to assess synergy versus additivity in clinical settings. We recently showed that because of extensive patient-to-patient heterogeneity in single drug responsiveness, increasing the chance of a good response to at least one drug was a quantitatively sufficient explanation for the clinical efficacy of many approved combination therapies. Some combinations surpass this ‘highest single-agent’ model, which could be due to either drug additivity or synergy. Here we propose and test a model of drug additivity for Progression-Free Survival (PFS) data from clinical trials, to identify if any approved combinations are clinically synergistic, as compared to additive. METHODS We used PFS from trials as the clinical measure of drug efficacy. We defined ‘clinical drug additivity’ as the sum of PFS times observed from each drug in a combination. Inter-patient heterogeneity in drug responses was simulated by sampling from the joint distribution of drugs’ PFS distributions. For each combination, the clinically observed PFS distribution was compared to the additivity model, or the highest single-agent model (Palmer & Sorger, 2017). Synergy is exhibited if an observed PFS distribution is significantly superior to PFS expected from additivity (by Cox Proportional Hazards). To search for drug synergy in clinical data, we analyzed approved combination therapies where synergy was most likely to explain efficacy, which are combinations where part of the regimen is not approved as monotherapy in the same disease. We analyzed 11 approved combination therapies for advanced cancers in the breast, ovary, pancreas, colon, cervix, and lymphatic system. RESULTS None of the 11 approved combinations analyzed were significantly superior to the model of clinical additivity. For five combinations, the additivity model made the most accurate predictions of clinical efficacy (mean R2=0.97 for additivity, versus R2=0.83 for highest single-agent), and the other six combinations were most accurately described by the highest single-agent model (mean R2=0.97 for highest single-agent, versus R2=0.91 for additivity). CONCLUSIONS Approved combination therapies are rarely ‘more than the sum of their parts’ in quantitative terms. A straightforward definition of clinical drug additivity accurately matched trial results for combination therapies where synergy was expected. This suggests that single-agent efficacy by each drug is usually required for the clinical success of combination therapy. Citation Format: Haeun Hwangbo, Adam C. Palmer. Defining and evaluating drug additivity in clinical trials of combination cancer therapy [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 2739.
Стилі APA, Harvard, Vancouver, ISO та ін.
Більше джерел

Дисертації з теми "Combination drug therapies"

1

Phee, Lynette. "Unorthodox antimicrobial combination therapies for the treatment of multi-drug resistant Gram-negative infections." Thesis, Queen Mary, University of London, 2018. http://qmro.qmul.ac.uk/xmlui/handle/123456789/44695.

Повний текст джерела
Анотація:
The rise of antimicrobial resistance (AMR) has culminated in the most pressing problem in modern medicine. The situation is most acute with regards to the management of multi- drug resistant Gram-negative infections (MDRGNB) with common infections increasingly untreatable due to rapidly dwindling therapeutic options. A solution to the problem of AMR is unlikely to be easily found, but revisiting and re-purposing existing antimicrobials is a viable approach in the medium term. This study investigated the use of unorthodox antimicrobial combination therapies for the treatment of MDRGNB, with particular focus on agents of last resort. A systematic review of clinical studies highlighted the potential for polymyxin (colistin) combination therapies (e.g. colistin-rifampicin, colistin-carbapenems), although this could not be supported in a formal meta-analysis. A systematic approach for screening MDRAB for susceptibility to novel colistin combinations using multiple methods was employed and uncovered a number that were more potent than those previously identfied. The most potent combination that was consistently identified was colistin when combined with fusidic acid, despite this drug having no useful activity against MDRGNB on its own. The combination was further evaluated in static time-kill assays against a range of Gram-negative pathogens with defined resistance mechanisms, including to polymyxins and using invertebrate (Galleria mellonella) and murine models of MDRGNB infection. Colistin and fusidic acid combination therapy was subsequently used to successfully treat a case of ventilator-associated pneumonia due to MDR A. baumannii. This work highlights how older drugs can be re-purposed to tackle the problem of AMR using a precision medicine approach. Further studies to elucidate the mechanism of action of the colistin- fusidic acid combination and a formal clinical trial are warranted to investigate the potential utility of this combination in the treatment of MDRGNB with the expressed goal of bridging the current antimicrobial development gap.
Стилі APA, Harvard, Vancouver, ISO та ін.
2

Gupta, Seema. "Experimental pharmacodynamic and kinetic studies related to new combination therapies against falciparum malaria /." Stockholm : Karolinska institutet, 2007. http://diss.kib.ki.se/2007/978-91-7357-066-4/.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
3

Nguyen, Tran Dang. "The effects of different deployment strategies of artemisinin combination therapies on slowing down the spread of antimalarial drug resistance : investigation with individual-based simulations." Thesis, Open University, 2016. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.700132.

Повний текст джерела
Анотація:
Despite the success of recent global malaria control efforts, which. have halved global malaria mortality since 2000, malaria is still one of the world's most deadly diseases causing an estimated half a million deaths, mostly among African children, and around a quarter of billion clinical episodes every year as reported in 2014 1. Drug resistance is one of the most important challenges to malaria elimination. To contain drug resistance, many efforts have been put forth including improvement of surveillance systems and mass treatment in order. to stop or slow down the transmission of the resistant strain. To find out whether a population-level treatment strategy can have any benefit in containing drug resistance, mathematical models are an appropriate approach to this problem and individual-based models allow us to have a better understanding of the effect of individual heterogeneities on the outcome. The first part of the thesis is about building and validating an individual based microsimulation. The model is implemented as an individual-based discrete-time event simulation model in C++. The behaviors and the state changes of human individuals are determined by relevant events and mathematical formulas. This integrated model combines components that reproduce the most important features of malaria transmission and epidemiology: the infectiousness of human populations; clinical model of acute illness; heterogeneities in individuals' age, biting-rate level, drug absorption, drug action, multiple parasite populations, and human immunity. To validate this individual-based model, two types of validation have been done. The model's parameters were obtained from field or clinical data were used directly in the model. For those parameters that cannot be obtained directly from literature review, sensitivity analysis has been done to find how variation in parameter values affects certain key features of malaria epidemiology .
Стилі APA, Harvard, Vancouver, ISO та ін.
4

Pace, Emily A. "Investigating combinatorial ligand addiction provides insights into rational drug combinations in cancer therapy." Thesis, Boston University, 2012. https://hdl.handle.net/2144/34647.

Повний текст джерела
Анотація:
Thesis (Ph.D.)--Boston University
PLEASE NOTE: Boston University Libraries did not receive an Authorization To Manage form for this thesis or dissertation. It is therefore not openly accessible, though it may be available by request. If you are the author or principal advisor of this work and would like to request open access for it, please contact us at open-help@bu.edu. Thank you.
Cancer, the second most common cause of death in the United States, is a collection of diseases caused by uncontrolled cell growth and metastasis. The main treatment for cancer is chemotherapy, which generally kills fast growing cells nonspecifically and has many side effects. A different type of cancer treatment, called targeted therapy, aims to avoid general toxicity by using drugs that block the activity of specific gene products, usually encoded by oncogenes, which have been shown to drive tumor growth. To date, targeted therapies, alone or in combination with chemotherapies, have mainly been successful in rare subsets of patients with tumors addicted to single oncogenes. This has created a rationale to mainly treat patients with an oncogene-addiction (such as those carrying mutated or overexpressed kinases) with targeted therapies like erlotinib and trastuzumab, which inhibit human epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2/ErbB2), respectively. Here, evidence is provided that targeted therapies are also effective in tumors that are dependent on multiple growth factors - a phenomenon that is called combinatorial ligand addiction. Specifically, it is shown that ligands that bind the EGFR family and the hepatocyte growth factor receptor (HGFR/MET) can activate protein kinase B (PKB/ AKT) across a broad set of cancer cell lines, suggesting that ligand signaling is redundant and widespread. It is also shown that ErbB ligands have distinct signaling dynamics and strengths, which provides a rationale for investigating each component of the ErbB signaling network. Using a systematic approach, we found that ErbB3 is an imp01tant therapeutic target even though it is not overexpressed and lacks kinase activity. Furthermore, it is shown that cell lines with and without known oncogene-addiction express autocrine ligands and have improved growth inhibition with drug combinations that include autocrine ligand-blocking antibodies. This research demonstrates that combinatorial ligand addiction creates a new rationale for therapeutic combinations to improve efficacy and prevent resistance in cancer cells that are treated with current targeted drugs.
2031-01-01
Стилі APA, Harvard, Vancouver, ISO та ін.
5

Peralta, Donna V. "Synthesis and Applications of Mutimodal Hybrid Albumin Nanoparticles for Chemotherapeutic Drug Delivery and Phototherml Therapy Platforms." ScholarWorks@UNO, 2014. http://scholarworks.uno.edu/td/1886.

Повний текст джерела
Анотація:
Progress has been made in using human serum albumin nanoparticles (HSAPs) as carrier systems for targeted treatment of cancer. Human serum albumin (HSA), the most abundant human blood protein, can form HSAPs via a desolvation and crosslinking method, with the size of the HSAPs having crucial importance for drug loading and in vivo performance. Gold nanoparticles have also gained medicinal attention due to their ability to absorb near-infrared (NIR) light. These relatively non-toxic particles offer combinational therapy via imaging and photothermal therapy (PPTT) capabilities. A desolvation and crosslinking approach was employed to encapsulate gold nanoparticles (AuNPs), hollow gold nanoshells (AuNSs), and gold nanorods (AuNRs), into efficiently sized HSAPs for future tumor heat ablation via PPTT. The AuNR-HSAPs, AuNP-HSAPs and AuNS-HSAPs had average particle diameters of 222 ± 5, 195 ± 9 and 156 ± 15, respectively. We simultaneously encapsulated AuNRs and the anticancer drug paclitaxel (PAC), forming PAC-AuNR-HSAPs with overall average particle size of 299 ± 6 nm. Loading of paclitaxel into PAC-AuNR-HSAPs reached 3μg PAC/mg HSA. PAC-AuNR-HSAPs experienced photothermal heating of 46 ˚C after 15 minutes of NIR laser exposure; the temperature necessary to cause severe cellular hyperthermia. There was a burst release of paclitaxel up to 188 ng caused by the irradiation session, followed by a temporal drug release. AuNR-HSAPs were tested for ablation of renal cell carcinoma using NIR irradiation in vitro. Particles created with the same amount of AuNRs, but varying HSA (1, 5 or 20 mg) showed overall particle size diameters 409 ± 224, 294 ± 83 and 167 ± 4 nm, respectively. Increasing HSAPs causes more toxicity under non-irradiated treatment conditions: AuNR-HSAPs with 20 mg versus 5 mg HSA caused cell viability of 64.5% versus 87%, respectively. All AuNR-HSAPs batches experienced photothermal heating above 42 ˚C. Coumarin-6, was used to visualize the cellular uptake of AuNR-HSAPs via fluorescence microscopy. Finally, camptothecin (CPT) an antineoplastic agent and BACPT (7-butyl-10-aminocamptothecin) were loaded into HSAPs to combat their aqueous insolubility. BACPT-HSAPs loaded up to 5.25 micrograms BACPT/ mg of HSA. CPT encapsulation could not be determined. BACPT-HSAPs and CPT-HSAPs showed cytotoxicity to human sarcoma cells in vitro.
Стилі APA, Harvard, Vancouver, ISO та ін.
6

Chen, Yun-Ti, and 陳筠媞. "A new combination therapies on hepatocellular carcinoma by computational omics and structure-based drug design on membrane proteins and alternative splicing proteins." Thesis, 2018. http://ndltd.ncl.edu.tw/handle/44dyds.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.

Книги з теми "Combination drug therapies"

1

L, Goldstein Allan, Garaci E, Institute for Advanced Studies in Immunology & Aging., and International Symposium on Combination Therapies (2nd : 1992 : Acireale, Italy), eds. Combination therapies 2: Biological response modifiers in the treatment of cancer and infectious diseases. New York: Plenum Press, 1993.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
2

L, Goldstein Allan, Garaci E, Institute for Advanced Studies in Immunology & Aging., and International Symposium on Combination Therapies (1st : 1991 : Washington, D.C.), eds. Combination therapies: Biological response modifiers in the treatment of cancer and infectious diseases. New York: Plenum Press, 1992.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
3

Combination Therapies: Biological Response Modifiers in the Treatment of Cancer and Infectious Diseases. Springer, 2012.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
4

Goldstein, Allan L., and E. Garaci. Combination Therapies: Biological Response Modifiers in the Treatment of Cancer and Infectious Diseases. Springer, 2012.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
5

Goldstein, Allan L., and E. Garaci. Combination Therapies: Biological Response Modifiers in the Treatment of Cancer and Infectious Diseases. Springer London, Limited, 2012.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
6

Serpell, Mick G. Antineuropathic medication combination therapy. Edited by Paul Farquhar-Smith, Pierre Beaulieu, and Sian Jagger. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780198834359.003.0068.

Повний текст джерела
Анотація:
The landmark paper discussed in this chapter is ‘Morphine, gabapentin, or their combination for neuropathic pain’, published by Gilron et al. in 2005. Although combination drug therapies for neuropathic pain had long been suggested, this seminal paper provided the first evidence for efficacy of combination therapy of mechanistically distinct medications in analgesia, using morphine in combination with gabapentin in post-herpetic neuralgia or diabetic neuropathy. Combination therapy had greater efficacy than gabapentin alone and was equally effective as morphine alone but with a lower dose of morphine; however, this did not seem to translate into reduced side effects. To this day, precious little is known about what are the most effective combinations for neuropathic pain, and the need for large randomized controlled trials in this area is still as pressing it was back in 2005.
Стилі APA, Harvard, Vancouver, ISO та ін.
7

Mbabazi, Johnson. Combination of Drug Therapies Is Better Than Exercise Alone in Controlling HbA1c Levels Type 2 Diabetes Patients. Independently Published, 2019.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
8

Goldstein, Allan L., and E. Garaci. Combination Therapies 2: Biological Response Modifiers in the Treatment of Cancer and Infectious Diseases. Springer London, Limited, 2012.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
9

Combination Therapies 2: Biological Response Modifiers in the Treatment of Cancer and Infectious Diseases. Springer, 2012.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
10

Siebert, Stefan, Sengupta Raj, and Alexander Tsoukas. Non-pharmacological treatment of axial spondyloarthritis. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780198755296.003.0014.

Повний текст джерела
Анотація:
While drugs play a key role in reducing disease activity, non-pharmacological therapies are crucial in maintaining function, flexibility, and quality of life. Therefore, non-pharmacological therapy remains a key component in the optimal management of axial spondyloarthritis (axSpA), even in the era of biologics. Regular physical therapy allows patients to capitalize on the benefits of drug therapy and maintain optimal functional ability. Self-management and education strategies, supported by patient-support groups, facilitate independence and quality of life in chronic diseases. A proportion of patients with severe disease may require hip or spinal surgery. It is hoped that the availability of more effective drug therapies to control disease activity in axSpA will reduce the requirement for surgery in future. The optimal management of axSpA requires a combination of non-pharmacological and pharmacological treatments, for both initial and long-term management.
Стилі APA, Harvard, Vancouver, ISO та ін.
Більше джерел

Частини книг з теми "Combination drug therapies"

1

Naing, Aung, Gordon B. Mills, and Funda Meric-Bernstam. "Combination Therapies Targeting the PI3K/AKT/mTOR Pathways." In Cancer Drug Discovery and Development, 151–80. Cham: Springer International Publishing, 2016. http://dx.doi.org/10.1007/978-3-319-34211-5_6.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
2

Dey, Nandini, Brian Leyland-Jones, and Pradip De. "HER2 Signaling Network in Advanced Breast Cancer: Opportunities for Combination Therapies." In Cancer Drug Discovery and Development, 231–61. Cham: Springer International Publishing, 2016. http://dx.doi.org/10.1007/978-3-319-34211-5_8.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
3

Giembycz, Mark A., and Robert Newton. "Harnessing the Clinical Efficacy of Phosphodiesterase 4 Inhibitors in Inflammatory Lung Diseases: Dual-Selective Phosphodiesterase Inhibitors and Novel Combination Therapies." In Phosphodiesterases as Drug Targets, 415–46. Berlin, Heidelberg: Springer Berlin Heidelberg, 2011. http://dx.doi.org/10.1007/978-3-642-17969-3_18.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
4

Cheah, Phaik Yeong, Michael Parker, and Nicholas P. J. Day. "Ethics and Antimalarial Drug Resistance." In Ethics and Drug Resistance: Collective Responsibility for Global Public Health, 55–73. Cham: Springer International Publishing, 2020. http://dx.doi.org/10.1007/978-3-030-27874-8_4.

Повний текст джерела
Анотація:
Abstract There has been impressive progress in malaria control and treatment over the past two decades. One of the most important factors in the decline of malaria-related mortality has been the development and deployment of highly effective treatment in the form of artemisinin-based combination therapies (ACTs). However, recent reports suggest that these gains stand the risk of being reversed due to the emergence of ACT resistance in the Greater Mekong Subregion and the threat of this resistance spreading to Africa, where the majority of the world’s malaria cases occur, with catastrophic consequences. This chapter provides an overview of strategies proposed by malaria experts to tackle artemisinin-resistant malaria, and some of the most important practical ethical issues presented by each of these interventions. The proposed strategies include mass antimalarial drug administrations in selected populations, and mandatory screening of possibly infected individuals prior to entering an area free of artemisinin-resistant malaria. We discuss ethical issues such as tensions between the wishes of individuals versus the broader goal of malaria elimination, and the risks of harm to interventional populations, and conclude by proposing a set of recommendations.
Стилі APA, Harvard, Vancouver, ISO та ін.
5

Perno, C. F., A. Bergamini, G. Milanese, M. Capozzi, G. Zon, R. Calio, and G. Rocchi. "Cytokines Modulate HIV Replication and the Activity of Antiviral Drugs in Cells of Monocyte/Macrophage Lineage." In Combination Therapies, 167–76. Boston, MA: Springer US, 1992. http://dx.doi.org/10.1007/978-1-4615-3340-5_20.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
6

Bakar, Nurzahidah, F. Merlin Franco, and Noor Hasharina Hassan. "The Intersection of Kedayan Folk Medicine and Traditional Ecological Calendar." In Case Studies in Biocultural Diversity from Southeast Asia, 105–24. Singapore: Springer Nature Singapore, 2022. http://dx.doi.org/10.1007/978-981-16-6719-0_5.

Повний текст джерела
Анотація:
AbstractA noteworthy feature of folk and codified traditional medicines is their ability to combine drug-based therapies with spiritual therapies. This unique combination differentiates them from the drug-based approach employed by modern biomedicine and renders them highly relevant to contemporary healthcare. Like folk medicine, traditional ecological calendars also embody the traditional knowledge held by local communities. However, the influence of ecological calendars on folk medicine has been largely underexplored; studies have mostly considered ecological calendars and folk medicine independent of each other. In this chapter, we provide an understanding of the traditional knowledge of the Kedayan community of Brunei Darussalam with specific reference to their folk medicine and their traditional ecological calendar. Data was collected through in-depth interviews that the first author held with sixteen knowledgeable elders from the Kedayan community of Brunei Darussalam between January 2018 and June 2018. The Kedayan classify causes of ailments broadly into two: ailments caused by factors of the unseen realm and factors of the seen realm. The former are treated by spiritual therapies and the latter using practices rooted in the humoral concept of well-being. The Kedayan traditional ecological calendar stipulates the right time for harvesting medicinal herbs and administering them. It links the potency of medicinal herbs to tidal cycles and also provides information on the seasonal occurrence of ailments. By focussing on the interface between the Kedayan folk medicine and the ecological calendar, the chapter draws attention to a hitherto underexplored area in folk medicine.
Стилі APA, Harvard, Vancouver, ISO та ін.
7

Sarin, Prem S., Allan Goldstein, S. Agrawal, and Paul Zamecnik. "Use of Drugs Targeted to Inhibit Different Stages of the HIV Life Cycle in the Treatment of AIDS." In Combination Therapies, 123–29. Boston, MA: Springer US, 1992. http://dx.doi.org/10.1007/978-1-4615-3340-5_15.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
8

Hildebrand, Keith R. "Device-Enabled Drug Infusion Therapies." In Drug-Device Combinations For Chronic Diseases, 182–213. Hoboken, New Jersey: John Wiley & Sons, Inc., 2015. http://dx.doi.org/10.1002/9781119002956.ch07.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
9

De Pauw, Ines, Carolien Boeckx, and An Wouters. "Mechanisms of Cetuximab Resistance and How to Overcome It." In Critical Issues in Head and Neck Oncology, 21–51. Cham: Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-63234-2_3.

Повний текст джерела
Анотація:
AbstractDeregulated or increased signalling of the epidermal growth factor receptor (EGFR) plays an integral role in the development of various cancer types, including head and neck squamous cell carcinoma (HNSCC), making it a compelling drug target. However, after initially promising results of EGFR-targeted therapies, such as the monoclonal antibody cetuximab, it became clear that both intrinsic and acquired therapeutic resistance are major roadblocks in the field of personalised cancer treatments.In order to unravel and overcome resistance to cetuximab, at least two strategies can be adopted.Firstly, therapeutic resistance to anti-EGFR therapy may arise from mechanisms that can compensate for reduced EGFR signalling and/or mechanisms that can modulate EGFR-dependent signalling. In this chapter, we discuss which mechanisms of cetuximab resistance are already known and which ones deserve further investigation. This enhanced knowledge will guide us to rationally design and test novel combination therapies that overcome resistance to EGFR-targeting agents in cancer treatment.Secondly, an urgent need remains to develop novel targeted treatments for single-agent or combined therapy use. In this view, due to the particular mode of activation of the EGFR receptor, involving ligand-induced homo- and heterodimerization of the four HER receptors, an increased inhibition scope of HER receptors most likely results in a more potent blockade of the HER network, preventing premature emergence of resistance and leading to a more pronounced therapeutic benefit. We discuss two multitargeted compounds, being MEHD7945A (duligotuzumab) and afatinib, in this chapter.Despite the huge efforts to unravel the molecular landscape of HNSCC, the main clinically validated target remains EGFR. However, immune checkpoints, like programmed cell death protein 1 (PD-1), are gaining clinical approvals as well. We underscore the importance of adopting rational drug combinations to enhance the therapeutic effect of the EGFR-inhibitor cetuximab and highlight the ongoing search for predictive biomarkers, with the ultimate goal of delivering individualized cancer therapy to HNSCC patients.
Стилі APA, Harvard, Vancouver, ISO та ін.
10

Sturrock, R. D. "The Use of DMARDs and Combination Therapies." In Side Effects of Anti-Inflammatory Drugs IV, 333. Dordrecht: Springer Netherlands, 1997. http://dx.doi.org/10.1007/978-94-011-5394-2_40.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.

Тези доповідей конференцій з теми "Combination drug therapies"

1

Reuveni, Hadas, Lana Kuperschmidt, Shani Carmi, Neta Moskovitz, Salomon Stemmer, and Izhak Haviv. "Abstract 4980: Rational design of combination therapies and block of acquired targeted drug resistance." In Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/1538-7445.am2015-4980.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
2

Brubaker, Doug, Svenson Elena, Kai Smith, Maya Monroe, Christopher Ryu, Mark R. Chance, Goutham Narla, and Gurkan Bebek. "Abstract PR04: Cancer drug response networks built for comparative cancer pharmacogenomics identifies combination therapies for repositioning." In Abstracts: AACR Special Conference: Translation of the Cancer Genome; February 7-9, 2015; San Francisco, CA. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/1538-7445.transcagen-pr04.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
3

Brubaker, Douglas, Elena Svenson, Smith Kai, Maya Monroe, Christopher Ryu, Goutham Narla, Mark R. Chance, and Gurkan Bebek. "Abstract B1-43: Cancer drug response networks built for comparative cancer pharmacogenomics identifies combination therapies for repositioning." In Abstracts: AACR Special Conference: Computational and Systems Biology of Cancer; February 8-11, 2015; San Francisco, CA. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/1538-7445.compsysbio-b1-43.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
4

Chen, Xintong, Gustavo Stolovitzky, and Bojan Losic. "Abstract 790: Coupled dynamics of drug synergy, gene expression, and alternative splicing in combination therapies in breast cancer." In Proceedings: AACR 107th Annual Meeting 2016; April 16-20, 2016; New Orleans, LA. American Association for Cancer Research, 2016. http://dx.doi.org/10.1158/1538-7445.am2016-790.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
5

Zoergiebel, Johanna, Abir Kundu, Johannes Braegelmann, Wanda Shen, Mohamed El Dinali, Ravi Salgia, and Tanguy Seiwert. "Abstract A165: Determining drug inhibition profiles and opportunities for synergistic combination therapies in head and neck cancer cell lines." In Abstracts: AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics--Nov 15-19, 2009; Boston, MA. American Association for Cancer Research, 2009. http://dx.doi.org/10.1158/1535-7163.targ-09-a165.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
6

Capaldo, Brian J., Devin G. Roller, Mark Axelrod, Alex Koeppel, Michael J. Weber, Aaron Mackey, Dan Gioeli, and Stefan Bekiranov. "Abstract 4166: Integrated molecular profiling of melanoma cell lines reveals genotype-drug phenotype associations giving insight on development of combination therapies." In Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA. American Association for Cancer Research, 2014. http://dx.doi.org/10.1158/1538-7445.am2014-4166.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
7

Ling, Alexander, and R. Stephanie Huang. "Abstract 5097: Clinical trial outcomes for drug combination therapies can be predicted by modeling independent action using cancer cell line screens." In Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.sabcs18-5097.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
8

Ling, Alexander, and R. Stephanie Huang. "Abstract 5097: Clinical trial outcomes for drug combination therapies can be predicted by modeling independent action using cancer cell line screens." In Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.am2019-5097.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
9

Fuchss, Thomas, Ulrich Graedler, Kai Schiemann, Daniel Kuhn, Holger Kubas, Heike Dahmen, Astrid Zimmermann, Frank Zenke, and Andree Blaukat. "Abstract 3500: Highly potent and selective ATM kinase inhibitor M4076: A clinical candidate drug with strong anti-tumor activity in combination therapies." In Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.am2019-3500.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
10

Fuchss, Thomas, Ulrich Graedler, Kai Schiemann, Daniel Kuhn, Holger Kubas, Heike Dahmen, Astrid Zimmermann, Frank Zenke, and Andree Blaukat. "Abstract 3500: Highly potent and selective ATM kinase inhibitor M4076: A clinical candidate drug with strong anti-tumor activity in combination therapies." In Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.sabcs18-3500.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.

Звіти організацій з теми "Combination drug therapies"

1

Gupta, Aditya, Tong Wang, Shruthi Ravi, Mesbah Talukder, Jessie Carviel, and Mary Bamimore. Relative efficacy of microneedling in the treatment of pattern hair loss: a protocol for a systematic review with network meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, September 2022. http://dx.doi.org/10.37766/inplasy2022.9.0042.

Повний текст джерела
Анотація:
Review question / Objective: The objective of the proposed study is to determine the relative efficacy of microneedling and combination of it and other agents for androgenetic alopecia (AGA)—a condition that is also referred to as pattern hair loss. Rationale: Pattern hair loss is one of the most common forms of hair loss in men and women; the condition is associated with decreased quality of life. Oral finasteride and topical minoxidil are treatments currently approved, by the United States Food and Drug Administration, for AGA. However, finasteride has been associated with significant side effects in men, and is not appropriate for women of childbearing potential. Furthermore, topical minoxidil requires daily prolonged use which is time-consuming for patients and requires high compliance to maintain efficacy. Due to these drawbacks, new treatments, such as microneedling, have been investigated. Microneedling involves the creation of small wounds on the scalp that prompt growth factor release and neovascularization—which, in turn, may promote hair growth. Microneedling has been used as a monotherapy—or in combination with other standard therapies—for the treatment of AGA. Further investigation through meta-analysis is salient as this quantitative technique can estimate the relative success of mono- and poly-therapy with microneedling; therefore, findings from a systematic review and meta-analysis on the comparative effectiveness can enable clinicians, patients, and researchers to make more informed decisions.
Стилі APA, Harvard, Vancouver, ISO та ін.
2

WANG, Xuesong, Xuliang SHI, Jing LV, Juncha ZHANG, Yongli HUO, Guang ZUO, Guangtong LU, Cunzhi LIU, and Yanfen SHE. Acupuncture and Related Therapies for anxiety and depression in Diarrhoea-Predominant Irritable Bowel Syndrome(IBS-D): A Network Meta-Analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, March 2022. http://dx.doi.org/10.37766/inplasy2022.3.0162.

Повний текст джерела
Анотація:
Review question / Objective: Acupuncture-related therapies are effective Diarrhoea-Predominant Irritable Bowel Syndrome(IBS-D), therefore, our aim was to evaluate and rank the effect of different acupuncture-related therapies for the anxiety-depression status of IBS-D patients. Eligibility criteria: The published randomized controlled trials (RCTs) of acupuncture-related therapies for the treatment of IBS-D, regardless of age and sex. Clear diagnostic criteria were required to confirm the diagnosis of IBS-D, Such as Rome I, Rome II, Rome III, Rome IV, and Chinese expert consensus. Interventions in the treatment group included various types of acupuncture-related therapies, including simple acupuncture (ACU), electroacupuncture (EA), warm acupuncture (WA), moxibustion (MOX), or a combination of acupuncture and drugs; the control group is anti-diarrheal or anti-spasmodic western medicine, or placebo, or comparison between various acupuncture-related therapies. The results of the report are required to include at least one of the following outcome indicators: (1) primary outcome: Hamilton anxiety rating scale( HAMA), hamilton depression rating scale(HAMD), self-rating anxiety scale (SAS), self-rating depression scale(SDS), secondary outcome: Response rate. The language of the publication was limited to Chinese or English.
Стилі APA, Harvard, Vancouver, ISO та ін.
3

Halker Singh, Rashmi B., Juliana H. VanderPluym, Allison S. Morrow, Meritxell Urtecho, Tarek Nayfeh, Victor D. Torres Roldan, Magdoleen H. Farah, et al. Acute Treatments for Episodic Migraine. Agency for Healthcare Research and Quality (AHRQ), December 2020. http://dx.doi.org/10.23970/ahrqepccer239.

Повний текст джерела
Анотація:
Objectives. To evaluate the effectiveness and comparative effectiveness of pharmacologic and nonpharmacologic therapies for the acute treatment of episodic migraine in adults. Data sources. MEDLINE®, Embase®, Cochrane Central Registrar of Controlled Trials, Cochrane Database of Systematic Reviews, PsycINFO®, Scopus, and various grey literature sources from database inception to July 24, 2020. Comparative effectiveness evidence about triptans and nonsteroidal anti-inflammatory drugs (NSAIDs) was extracted from existing systematic reviews. Review methods. We included randomized controlled trials (RCTs) and comparative observational studies that enrolled adults who received an intervention to acutely treat episodic migraine. Pairs of independent reviewers selected and appraised studies. Results. Data on triptans were derived from 186 RCTs summarized in nine systematic reviews (101,276 patients; most studied was sumatriptan, followed by zolmitriptan, eletriptan, naratriptan, almotriptan, rizatriptan, and frovatriptan). Compared with placebo, triptans resolved pain at 2 hours and 1 day, and increased the risk of mild and transient adverse events (high strength of the body of evidence [SOE]). Data on NSAIDs were derived from five systematic reviews (13,214 patients; most studied was ibuprofen, followed by diclofenac and ketorolac). Compared with placebo, NSAIDs probably resolved pain at 2 hours and 1 day, and increased the risk of mild and transient adverse events (moderate SOE). For other interventions, we included 135 RCTs and 6 comparative observational studies (37,653 patients). Compared with placebo, antiemetics (low SOE), dihydroergotamine (moderate to high SOE), ergotamine plus caffeine (moderate SOE), and acetaminophen (moderate SOE) reduced acute pain. Opioids were evaluated in 15 studies (2,208 patients).Butorphanol, meperidine, morphine, hydromorphone, and tramadol in combination with acetaminophen may reduce pain at 2 hours and 1 day, compared with placebo (low SOE). Some opioids may be less effective than some antiemetics or dexamethasone (low SOE). No studies evaluated instruments for predicting risk of opioid misuse, opioid use disorder, or overdose, or evaluated risk mitigation strategies to be used when prescribing opioids for the acute treatment of episodic migraine. Calcitonin gene-related peptide (CGRP) receptor antagonists improved headache relief at 2 hours and increased the likelihood of being headache-free at 2 hours, at 1 day, and at 1 week (low to high SOE). Lasmiditan (the first approved 5-HT1F receptor agonist) restored function at 2 hours and resolved pain at 2 hours, 1 day, and 1 week (moderate to high SOE). Sparse and low SOE suggested possible effectiveness of dexamethasone, dipyrone, magnesium sulfate, and octreotide. Compared with placebo, several nonpharmacologic treatments may improve various measures of pain, including remote electrical neuromodulation (moderate SOE), magnetic stimulation (low SOE), acupuncture (low SOE), chamomile oil (low SOE), external trigeminal nerve stimulation (low SOE), and eye movement desensitization re-processing (low SOE). However, these interventions, including the noninvasive neuromodulation devices, have been evaluated only by single or very few trials. Conclusions. A number of acute treatments for episodic migraine exist with varying degrees of evidence for effectiveness and harms. Use of triptans, NSAIDs, antiemetics, dihydroergotamine, CGRP antagonists, and lasmiditan is associated with improved pain and function. The evidence base for many other interventions for acute treatment, including opioids, remains limited.
Стилі APA, Harvard, Vancouver, ISO та ін.
Також вас можуть зацікавити розширені добірки на тему "Combination drug therapies" для конкретних типів джерел:
Статті в журналах Книги
Ми пропонуємо знижки на всі преміум-плани для авторів, чиї праці увійшли до тематичних добірок літератури. Зв'яжіться з нами, щоб отримати унікальний промокод!

До бібліографії